Palantir’s Double Headache: A UK Data Scrutiny and a Stock That Can’t Shake Its Slide
Published on 07/27/2026 at 08:21 | Redaktion boerse-global.de
Palantir Technologies finds itself caught between two very different narratives. On one hand, the company is notching strategic wins that should bolster its long-term prospects — including a legal victory that forced the US Defense Intelligence Agency to scrap a major surveillance contract bid. On the other, its stock has been battered by a combination of regulatory scrutiny in Britain, a broader software sector sell-off, and lingering valuation concerns that have erased nearly a third of its value since January.
The shares closed Friday at €107.90, down 0.5% on the day and 8.78% for the week. Year to date, the decline stands at 31.33%.
The NHS Data Dispute That Rattled Investors
The heaviest blow came midweek. On Wednesday, Palantir’s stock tumbled 6.1% — its steepest single-day drop of the week — after reports surfaced that the UK’s National Health Service had attached caveats to positive findings about Palantir’s health data platform. The Financial Times reported that a British statistical review had concluded the data presented could not demonstrate a causal link.
For a company already trading at elevated multiples, the timing could hardly have been worse. The news amplified pre-existing jitters ahead of Palantir’s upcoming quarterly results, due in August. Among comparable software stocks, Palantir suffered the worst weekly loss between July 17 and July 24. Rivals Salesforce and Snowflake also declined, but far more modestly. The Nasdaq Composite, by contrast, slipped just 2.1% over the same stretch — underscoring that company-specific headlines, not macro trends, are driving Palantir’s recent moves.
Should investors sell immediately? Or is it worth buying Palantir?
A Pentagon Win That Actually Matters
While the stock flounders, Palantir’s business operations tell a different story. In the final week of July, the company forced the Defense Intelligence Agency to withdraw a tender for the ASTRA reconnaissance system after filing a formal protest. The move reinforced Palantir’s central argument: that the government should leverage existing commercial software rather than building expensive custom solutions from scratch.
The victory is more than a prestige play. It cements Palantir’s role as a key provider of AI-powered military intelligence and shields its revenue stream from potential government-built competition. The win also arrived alongside a Citigroup upgrade late last month, with analysts citing an expected recovery in Palantir’s US commercial business and growing traction for its AIP platform across industries. Citi projects that commercial segment revenue could significantly exceed current estimates by 2027.
Open-Source Anxiety and a Market That’s Cooling Fast
Not all the headwinds are regulatory. Reports of free open-source competitors on GitHub have stoked nervousness among investors, contributing to last week’s 8.78% slide. Palantir’s management, however, has struck a calmer tone, arguing that the commoditization of AI models actually benefits the company because it provides the layer that makes those models usable for enterprises.
The broader software sector is also under pressure. Investors have been rotating out of SaaS names since Anthropic and OpenAI launched new model capabilities. Recent earnings reports from IBM and ServiceNow have accelerated the selling wave. Palantir’s 14-day relative strength index sits at 42.6 — neutral territory that suggests the stock is neither oversold nor overbought. Its annualized 30-day volatility of nearly 49% underscores just how sharp the swings have been.
The Numbers That Could Turn the Tide
Despite the stock’s struggles, the underlying business remains robust. In the first quarter, revenue surged 85% year over year, while gross margins expanded from 80% to 87%. US commercial revenue more than doubled to $595 million, and US government revenue climbed 84% to $687 million.
Palantir at a turning point? This analysis reveals what investors need to know now.
Those figures have done little to prop up the share price. Market observers view the roughly 25% decline this year as a correction following 2024’s massive rally, with fading AI euphoria adding to the cooling effect — even as the long-term order book remains intact.
Technically, Palantir is trading below all three major moving averages: the 50-day at €114.36, the 100-day at €119.25, and the 200-day at €131.56. The stock has recovered 15.65% from its 52-week low of €93.30 in late June, but remains roughly 40% below its high of €179.98.
Analyst consensus points to a price target of €160.97 — implying nearly 50% upside from current levels. Whether that gap closes depends on the August earnings report. If commercial growth meets expectations, the €107 area could eventually look like an attractive entry point. But first, the stock needs to reclaim its 50-day moving average — and convince investors that the UK data controversy is a distraction, not a turning point.
Ad
Palantir Stock: New Analysis - 27 July
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
